In clinical treatment of non-small cell lung cancer (NSCLC), the acquired resistance of the first generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) is a main factor leading to poor prognosis of NSCLC1. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.